Latest News
In a first of its kind study, BrightFocus-funded researchers have identified a possible new way to improve drugs to treat glaucoma by studying a tiny part of the eye’s drainage system that plays a major role in eye pressure.
A potential drug rooted in initial grant funding from BrightFocus Foundation to Dr. Ilyas Washington gives hope to those suffering from Stargardt disease, a genetic form of macular degeneration.
BrightFocus Foundation’s 2023 annual report highlights an incredible year of pioneering neurodegenerative research.
Vision scientists from across the globe will convene at BrightFocus Foundation’s second Macular Fast Track program on October 23 in Torremolinos, Spain. The immersive workshop, which serves as the pre-symposium of the International Symposium on Retinal Degeneration (RD2023), trains promising graduate students, postdoctoral fellows, and other early-career scientists focused on vision research to help speed progress toward a cure for macular degeneration.
As we mark World Sight Day today, October 12, BrightFocus Foundation reaffirms its commitment to funding breakthrough research for macular degeneration and glaucoma and providing valuable resources for people living with low vision.
Researchers have found a way to block a “master switch” in the eye and the brain that controls inflammation, introducing a possible target for combatting glaucoma and other neurodegenerative diseases.
On Friday, Oct. 13, BrightFocus and the International African American Museum hosted "Small Miracles: A Promise Toward a Future of Health and Wellness," an in-person and live-streamed panel discussion on the importance of equitable access to health care.
An updated drug shows promise in treating traumatic brain injuries that can lead to neurodegenerative diseases.
Researchers have successfully demonstrated that hagfish slime proteins can accurately replicate membranes in the human eye.
A team of researchers including Alzheimer’s Disease Research grantee Eunhee Kim, PhD, have used a 3D brain cell culture model to show that the exercise-induced muscle hormone, irisin, reduces the level of amyloid beta associated with Alzheimer’s disease.
